Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sikarin PCLBKK:SKR-R +12.86%90 Debt-to-EBITDA is 0.39 as of Jun. 2026, which is 66% below its 10-year median of 1.15. GuruFocus rates BKK:SKR-R with a GF Score™ of 90/100 and a GF Value™ of ฿8.11 (Fairly Valued). The stock has 5 warning signs investors should review. Among 483 Healthcare Providers & Services companies, Sikarin PCL ranks better than 83.23% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Sikarin PCL's Debt-to-EBITDA or its related term are showing as below:
BKK:SKR-R'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.38 Med: 1.15 Max: 2.33
Current: 0.38
During the past 13 years, the highest Debt-to-EBITDA Ratio of Sikarin PCL was 2.33. The lowest was 0.38. And the median was 1.15.
BKK:SKR-R's Debt-to-EBITDA is ranked better than 83.23% of 483
companies
in the Healthcare Providers & Services industry
Industry Median: 2.18
vs BKK:SKR-R: 0.38
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Sikarin PCL Debt-to-EBITDA Related Terms
Sikarin PCL Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Sikarin PCL's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BKK:SKR-R vs HCA, THC, DVA: Debt-to-EBITDA Comparison
For the Medical Care Facilities subindustry, Sikarin PCL's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sikarin PCL Debt-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Sikarin PCL's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Sikarin PCL's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Sikarin PCL (BKK:SKR-R) has a Debt-to-EBITDA of 0.39 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Sikarin PCL. This is 66% below median its historical median of 1.15. Over the past decade, Sikarin PCL's Debt-to-EBITDA has ranged from 0.38 to 2.33. According to the industry distribution chart, Sikarin PCL ranks #81 out of 483 companies in the Healthcare Providers & Services industry, placing it in the top 16.8%.
Is Sikarin PCL's Debt-to-EBITDA too high?
Sikarin PCL's current Debt-to-EBITDA of 0.39 is 66% below median its 10-year median of 1.15. Over the past 10 years, this metric has ranged from a low of 0.38 to a high of 2.33. The Healthcare Providers & Services industry median Debt-to-EBITDA is 2.18. Sikarin PCL's value of 0.39 is 82.1% below this industry median. Based on the distribution chart, Sikarin PCL ranks #81 out of 483 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Sikarin PCL has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sikarin PCL's Debt-to-EBITDA compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Sikarin PCL ranks #81 out of 483 companies for Debt-to-EBITDA. This places Sikarin PCL in the top 17% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 2.18. Sikarin PCL's value of 0.39 is 82.1% below this benchmark. Historically, Sikarin PCL's own Debt-to-EBITDA has ranged from 0.38 to 2.33 over the past decade. While the company's 10-year median is 1.15 vs. the industry median of 2.18, Sikarin PCL has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Healthcare Providers & Services company?
The median Debt-to-EBITDA among Healthcare Providers & Services companies is 2.18, based on 483 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sikarin PCL's current Debt-to-EBITDA of 0.39 is 82.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Sikarin PCL. For the Healthcare Providers & Services industry, the median Debt-to-EBITDA is 2.18 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sikarin PCL's current Debt-to-EBITDA is 0.39, which is 66% below median its own 10-year median of 1.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sikarin PCL stock overvalued right now?
Based on GuruFocus' analysis, Sikarin PCL (BKK:SKR-R) is currently considered Fairly Valued. The stock's GF Value™ is ฿8.11, compared to a current price of ฿7.85 — trading 3.2% below its estimated fair value. The current Debt-to-EBITDA is 0.39, which is 66% below median its 10-year median of 1.15 and 82.1% below the Healthcare Providers & Services industry median of 2.18. Sikarin PCL's overall GF Score™ is 90/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Sikarin PCL (BKK:SKR-R), the current Debt-to-EBITDA is 0.39 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sikarin PCL (BKK:SKR-R) Overvalued in 2026?
Based on GuruFocus' analysis, Sikarin PCL stock appears to be undervalued.
The current stock price of ฿7.85 is trading 3.2% below its estimated GF Value™ of ฿8.11.
GuruFocus considers Sikarin PCL to be Fairly Valued.
Key valuation signals for BKK:SKR-R:
Debt-to-EBITDA: 0.39 (66% below median its 10-year median of 1.15)
GF Value™: ฿8.11 vs. price of ฿7.85 (3.2% below fair value)
Industry Position: 82.1% below the Healthcare Providers & Services median (#81 of 483)
No single metric tells the full story. See the BKK:SKR-R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SSikarin PCL provides general healthcare services and operates under the social security system. The Group has one main operating segment, which is providing healthcare services through private hospitals and hospitals affiliated with the social security system. The Group operates in a single geographical area, which is Thailand. Its services include medical centers, a pediatric center, a women's institute, a radiology center, a neurology center, a rehabilitation center, and an orthopedic center.
90GF Score
Get the complete analysis for BKK:SKR-R
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:SKR-R has been successfully added to your 
